SLNO SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Soleno Therapeutics, Inc. Investors - Contact Kirby McInerney LLP by May 5, 2026

NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ:SLNO) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected] , or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

If you suffered a loss on your Soleno investments, you have until May 5, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.

Follow the link below for more information about the lawsuit:

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of March 26, 2025 through November 4, 2025, inclusive ("the Class Period"). The lawsuit alleges that (i) the Soleno Phase 3 clinical trial program for DCCR, trademarked as Vykat XR, had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related ...

Full story available on Benzinga.com